Terms: = Kidney tumors AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Treatment
237 results:
1. Crosstalk of disulfidptosis-related subtypes identifying a prognostic signature to improve prognosis and immunotherapy responses of clear cell renal cell carcinoma patients.
Ren L; Liu J; Lin Q; He T; Huang G; Wang W; Zhan X; He Y; Huang B; Mao X
BMC Genomics; 2024 Apr; 25(1):413. PubMed ID: 38671348
[TBL] [Abstract] [Full Text] [Related]
2. Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas.
Roskoski R
Pharmacol Res; 2024 May; 203():107181. PubMed ID: 38614375
[TBL] [Abstract] [Full Text] [Related]
3. Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001.
Montemagno C; Jacquel A; Pandiani C; Rastoin O; Dawaliby R; Schmitt T; Bourgoin M; Palenzuela H; Rossi AL; Ambrosetti D; Durivault J; Luciano F; Borchiellini D; Le Du J; Gonçalves LCP; Auberger P; Benhida R; Kinget L; Beuselinck B; Ronco C; Pagès G; Dufies M
J Exp Clin Cancer Res; 2024 Mar; 43(1):86. PubMed ID: 38504270
[TBL] [Abstract] [Full Text] [Related]
4. Immune Modulation with RANKL Blockade through Denosumab treatment in Patients with Cancer.
Chang H; Marquez J; Chen BK; Kim DM; Cheng ML; Liu EV; Yang H; Zhang L; Sinha M; Cheung A; Kwek SS; Chow ED; Bridge M; Aggarwal RR; Friedlander TW; Small EJ; Anderson M; Fong L
Cancer Immunol Res; 2024 Apr; 12(4):453-461. PubMed ID: 38276989
[TBL] [Abstract] [Full Text] [Related]
5. Systematic Multiomic Analysis of
Kang JY; Yang J; Lee H; Park S; Gil M; Kim KE
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203530
[TBL] [Abstract] [Full Text] [Related]
6. Pyroptosis-Related Subtypes Predict the Response of Clear Cell Renal Cell Carcinoma to Targeted Therapy.
Ma J; Kang Z; Yang G; Wang X; Si M; Wang Y; Li G; Bai S; Zeng F; Li M; Wang Z; Wang L; Xu W
Front Biosci (Landmark Ed); 2023 Dec; 28(12):334. PubMed ID: 38179741
[TBL] [Abstract] [Full Text] [Related]
7. Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview.
Kejamurthy P; Devi KTR
Med Oncol; 2023 Dec; 41(1):40. PubMed ID: 38158454
[TBL] [Abstract] [Full Text] [Related]
8. Knockdown of ADAM8 inhibits the proliferation, migration, invasion, and tumorigenesis of renal clear cell carcinoma cells to enhance the immunotherapy efficacy.
Qu H; Mao M; Wang K; Mu Z; Hu B
Transl Res; 2024 Apr; 266():32-48. PubMed ID: 37992987
[TBL] [Abstract] [Full Text] [Related]
9. Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma.
Jang A; Lichterman JN; Zhong JY; Shoag JE; Garcia JA; Zhang T; Barata PC
Hum Vaccin Immunother; 2023 Dec; 19(3):2276629. PubMed ID: 37947202
[TBL] [Abstract] [Full Text] [Related]
10. Unraveling the prognostic significance and molecular characteristics of tumor-infiltrating B lymphocytes in clear cell renal cell carcinoma through a comprehensive bioinformatics analysis.
Yue Y; Cai X; Lu C; Sechi LA; Solla P; Li S
Front Immunol; 2023; 14():1238312. PubMed ID: 37908350
[TBL] [Abstract] [Full Text] [Related]
11. Inflammatory response-based prognostication and personalized therapy decisions in clear cell renal cell cancer to aid precision oncology.
Zhong W; Chen H; Yang J; Huang C; Lin Y; Huang J
BMC Med Genomics; 2023 Oct; 16(1):265. PubMed ID: 37885006
[TBL] [Abstract] [Full Text] [Related]
12. LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma.
Choueiri TK; Powles T; Voss MH; Plimack ER; Gurney H; Song Y; Perini RF; Rodriguez-Lopez K; Rini BI
Future Oncol; 2023 Dec; 19(40):2631-2640. PubMed ID: 37882432
[TBL] [Abstract] [Full Text] [Related]
13. Construction of the metabolic reprogramming-associated gene signature for clear cell renal cell carcinoma prognosis prediction.
Tai R; Leng J; Li W; Wu Y; Yang J
BMC Urol; 2023 Sep; 23(1):147. PubMed ID: 37715154
[TBL] [Abstract] [Full Text] [Related]
14. The multi-omics analyses of acsl1 reveal its translational significance as a tumor microenvironmental and prognostic biomarker in clear cell renal cell carcinoma.
Yang Y; Liang J; Zhao J; Wang X; Feng D; Xu H; Shen Y; Zhang Y; Dai J; Wang Z; Wei Q; Liu Z
Diagn Pathol; 2023 Aug; 18(1):96. PubMed ID: 37608295
[TBL] [Abstract] [Full Text] [Related]
15. Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases.
Schoenfeld DA; Moutafi M; Martinez S; Djureinovic D; Merkin RD; Adeniran A; Braun DA; Signoretti S; Choueiri TK; Parisi F; Hurwitz M; Rimm DL; Wei W; Jilaveanu L; Kluger HM
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586773
[TBL] [Abstract] [Full Text] [Related]
16. Morbidity of elective surgery for localized renal masses among elderly patients: A contemporary multicenter study.
Borregales LD; Pecoraro A; Roussel E; Mari A; Grosso AA; Checcucci E; Montorsi F; Larcher A; Van Poppel H; Porpiglia F; Capitanio U; Minervini A; Albersen M; Serni S; Amparore D; Campi R
Eur J Surg Oncol; 2023 Oct; 49(10):107014. PubMed ID: 37573666
[TBL] [Abstract] [Full Text] [Related]
17. A novel prognostic signature of chemokines for survival and immune infiltration in kidney renal clear cell carcinoma.
Weng J; Huang Z; Li Q; Huang Y; Chen S
Int J Med Sci; 2023; 20(8):1046-1059. PubMed ID: 37484803
[No Abstract] [Full Text] [Related]
18. Meta-analysis of perioperative immunotherapy in renal cell carcinoma: Available, but the jury is still out.
Esteban-Villarrubia J; Romero Ferreiro C; Carril-Ajuria L; Carretero-González A; Iacovelli R; Albiges L; Castellano D; de Velasco G
Urol Oncol; 2023 Sep; 41(9):391.e13-391.e21. PubMed ID: 37331822
[TBL] [Abstract] [Full Text] [Related]
19. Development of a novel modified vaccine (TheraVac
Masud Alam M; Huang Y; Oppenheim JJ; Yang D
Cytokine; 2023 Sep; 169():156270. PubMed ID: 37302280
[TBL] [Abstract] [Full Text] [Related]
20. Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors.
Oppolzer IA; Riester J; Büttner R; Burger M; Schnabel MJ
Int Urol Nephrol; 2023 Aug; 55(8):1943-1949. PubMed ID: 37271776
[TBL] [Abstract] [Full Text] [Related]
[Next]